Fauna Bio, a biotechnology company pioneering the use of extreme mammal biology and comparative genomics to discover novel therapeutic targets, today announced the designation of a target under its ...
FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results